sb 203580 has been researched along with xanthohumol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (xanthohumol) | Trials (xanthohumol) | Recent Studies (post-2010) (xanthohumol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 408 | 11 | 290 |
| Protein | Taxonomy | sb 203580 (IC50) | xanthohumol (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 6.6 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 2.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capasso, A; D'Acunto, CW; Festa, M; Masullo, M; Piacente, S; Pizza, C; Rossi, AG | 1 |
1 other study(ies) available for sb 203580 and xanthohumol
| Article | Year |
|---|---|
Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cyclohexenes; Cytochromes c; Dose-Response Relationship, Drug; Flavonoids; Glioblastoma; Humans; Imidazoles; Italy; Mitogen-Activated Protein Kinases; Molecular Structure; Poly(ADP-ribose) Polymerases; Propiophenones; Pyridines; Reactive Oxygen Species; Terpenes | 2011 |